RecruitingPhase 1NCT06771219

SLV-154 Treatment of Metastatic Solid Tumors

A Phase 1 Dose-Escalation Study of SLV-154 in Subjects With Metastatic Solid Tumors


Sponsor

Solve Therapeutics

Enrollment

70 participants

Start Date

May 14, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with metastatic solid tumors.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new drug called SLV-154 in people with various types of metastatic solid tumors (cancers that have spread to other organs), including head and neck cancer, lung cancer (small cell and non-small cell), breast cancer, cervical cancer, and others. The goal is to find a safe dose and see if the drug works. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of one of the qualifying cancer types (e.g., head and neck, lung, breast, cervical) - Your cancer has spread (metastatic) and prior treatments have not worked - Your general health is adequate (ECOG 0-2) - You have measurable disease on imaging **You may NOT be eligible if...** - You have active brain metastases not previously treated with radiotherapy - You have another active cancer requiring treatment - You have severe heart, liver, or kidney problems - You are pregnant or breastfeeding - You received recent chemotherapy and have not recovered from its side effects Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSLV-154

SLV-154


Locations(9)

Hoag Memorial Hospital Presbyterian

Newport Beach, California, United States

Washington University

St Louis, Missouri, United States

Astera Cancer Care

East Brunswick, New Jersey, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

MD Anderson Cancer Center

Houston, Texas, United States

Oncology Consultants

Houston, Texas, United States

Mays Cancer Center; University of Texas Health San Antonio

San Antonio, Texas, United States

University of Washington / Fred Hutchinson Cancer Center

Seattle, Washington, United States

Northwest Medical Specialties, PLLC

Tacoma, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06771219


Related Trials